Bristol-Myers Squibb Co. reported its fourth quarter earnings Tuesday morning. Here's what investors need to know.
3 Motley Fool contributors offer up suggestions on what they believe Pfizer should acquire.
Our Motley Fool contributors think that these three companies could one day be as revered as J&J.
AbbVie's most important product, Humira, will lose patent exclusivity in the U.S. in 2016. Should investors fear this upcoming event?
AbbVie highlighted its hepatitis C and oncology growth opportunities at the annual JP Morgan Healthcare Conference.
Shares of cancer diagnostic maker Foundation Medicine more than doubled Monday morning. Here's why.
Celgene Corp, Alkermes, GW Pharmaceuticals, Gilead Sciences, and Hospira should all be on investors radar in 2015.
There are few stocks as exciting as Gilead Sciences. But, that doesn't mean there aren't headwinds which could send its shares significantly lower. Here are three such headwinds that Wall Street may be overlooking.
Gilead Sciences looks cheap based on its present valuation metrics and growth prospects going forward. Will a growth-starved big pharma decide to pursue a merger with this high flying biotech in 2015?
After failing to complete a buyout of Irish biopharma Shire, AbbVie was reported to be a potential takeover target. Is this top drugmaker an attractive acquisition target for growth-starved big pharma in 2015?